查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049127

H1N1疫苗市場報告：依疫苗類型、市場類型和地區分類（2026-2034年）

H1N1 Vaccines Market Report by Vaccine Type (Intramuscular, Intranasal, Intradermal), Market Type (Public, Private), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年全球H1N1疫苗市場規模達40億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到57億美元，2026年至2034年的複合年成長率為3.87%。推動市場成長的主要因素包括：人們健康意識的提高、醫療技術的顯著進步、醫療保健系統的改善以及對H1N1疫苗重要性的日益重視。

H1N1疫苗（也稱為甲型H1N1流感疫苗）旨在預防H1N1型流感病毒感染。這種病毒株俗稱“豬流感”，曾在2009年引發全球大流行。 H1N1疫苗含有去活化或減毒的病毒或其成分，能夠刺激免疫系統產生針對H1N1病毒株的抗體。這些疫苗有助於預防感染並控制病毒傳播。它們通常包含在季節性流感疫苗配方中，提供針對H1N1以及其他常見流感病毒株的免疫力。

流感大流行的持續威脅凸顯了有效疫苗在預防H1N1病毒傳播的重要性，這也是全球H1N1疫苗市場成長的主要促進因素之一。高感染率和潛在的重症風險推動了公眾對疫苗的需求。人們對疫苗益處的認知不斷提高，以及各國政府為推廣免疫計畫所做的努力，正在加速疫苗的分發，進一步促進市場成長。公共衛生宣傳活動和提高公眾意識的措施也有助於提高疫苗接種率。此外，全球人口的相互連結日益緊密，也增加了預防措施的必要性。國際旅行和貿易加速了感染疾病的傳播，因此制定強力的疫苗接種策略至關重要。製藥公司、研究機構和衛生組織之間的合作也在促進創新，並確保疫苗的及時研發。監管支持和簡化的核准流程正在推動疫苗研發和生產方面的投資，為全球市場創造了良好的前景。

H1N1疫苗市場趨勢及促進因素：

加強疫情防治措施

未來疫情大流行的威脅日益加劇，推動了市場成長，各國政府、醫療機構和個人都將接種疫苗作為預防措施。為最大限度減少感染疾病傳播並保護弱勢群體，對H1N1疫苗的需求不斷成長。此外，醫療基礎設施的改善和政府醫療預算的增加也促進了市場成長。

擴大公共衛生舉措

世界各國政府和衛生部門正日益開展公共衛生宣傳活動，推廣H1N1疫苗接種，提高大眾對疫苗益處的認知，這推動了疫苗市場的成長。這些努力著重於公眾教育，消除錯誤訊息，並積極鼓勵接種疫苗，以確保對病毒的廣泛保護。這些宣傳活動有助於提高疫苗接種率和增強群體免疫力。各國政府也致力於改善醫療設施，使其更方便偏遠地區和弱勢族群獲得醫療服務，進而促進疫苗接種。

海外旅行增加和交通便利性提高

國際旅行和互聯互通的增加正在加速H1N1等感染疾病的傳播，進一步推高了對H1N1疫苗的需求。世界各地人口的相互連結凸顯了群體免疫在控制疫情傳播上的重要性。 H1N1疫苗透過為旅客提供保護，降低輸入性病例和後續感染的風險，在減少跨境傳播的可能性方面發揮著至關重要的作用。

目錄

第1章：序言

第2章：分析的範圍與方法

  • 分析目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 分析方法

第3章執行摘要

第4章：引言

第5章：全球H1N1疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依疫苗類型
  • 市場區隔：依市場類型
  • 主要藥品品牌分析
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 肌肉內部
  • 鼻內給藥
  • 皮下

第7章 市場區隔：依市場類型分類

  • 民眾
  • 私人的

第8章 市場區隔：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第9章：主要品牌藥物分析

  • Agripal
  • Fiuarix
  • Influgen
  • Influvac
  • Nasovac
  • Vaxigrip
  • 其他

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

  • 價格指標
  • 價格結構
  • 利潤分析

第14章 產業趨勢

  • 開發平臺與新產品發布
  • 企業合併、商業夥伴關係

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • CPL Biologicals Pvt. Ltd
    • CSL Limited
    • Zoetis Inc.
Product Code: SR112026A1314

The global H1N1 vaccines market size reached USD 4.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.87% during 2026-2034. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as "swine flu," caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.

The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.

H1N1 VACCINES MARKET TRENDS/DRIVERS:

Rise in pandemic preparedness

The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.

Rising public health initiatives

Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.

Rise in global travel and connectivity

Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.

H1N1 VACCINES INDUSTRY SEGMENTATION:

Breakup by Vaccine Type:

  • Intramuscular
  • Intranasal
  • Intradermal

Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.

Breakup by Market Type:

  • Public
  • Private

H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.

COMPETITIVE LANDSCAPE:

Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • AstraZeneca plc
  • CPL Biologicals Pvt. Ltd
  • CSL Limited
  • Zoetis Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global H1N1 vaccines market in 2025?
  • 2.What is the expected growth rate of the global H1N1 vaccines market during 2026-2034?
  • 3.What are the key factors driving the global H1N1 vaccines market?
  • 4.What has been the impact of COVID-19 on the global H1N1 vaccines market?
  • 5.What is the breakup of the global H1N1 vaccines market based on the vaccine type?
  • 6.What is the breakup of the global H1N1 vaccines market based on the market type?
  • 7.What are the key regions in the global H1N1 vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global H1N1 Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Breakup by Vaccines Type
  • 5.5 Breakup by Market Type
  • 5.6 Analysis of Key Brands
  • 5.7 Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Vaccines Type

  • 6.1 Intramuscular
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intranasal
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Intradermal
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Public
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Private
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Analysis of Key Brand

  • 9.1 Agripal
  • 9.2 Fiuarix
  • 9.3 Influgen
  • 9.4 Influvac
  • 9.5 Nasovac
  • 9.6 Vaxigrip
  • 9.7 Others

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

  • 13.1 Price Indicators
  • 13.2 Price Structure
  • 13.3 Margin Analysis

14 Industry Developments

  • 14.1 Pipeline and New Product Launches
  • 14.2 Mergers & Acquisitions and Partnerships

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CPL Biologicals Pvt. Ltd
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Zoetis Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis

List of Figures

  • Figure 1: Global: H1N1 Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: H1N1 Vaccines Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: H1N1 Vaccines Market: Breakup by Vaccines Type (in %), 2025
  • Figure 4: Global: H1N1 Vaccines Market: Breakup by Type (in %), 2025
  • Figure 5: Global: H1N1 Vaccines Market: Breakup by Region (in %), 2025
  • Figure 6: Global: H1N1 Vaccines Industry: SWOT Analysis
  • Figure 7: Global: H1N1 Vaccines Industry: Value Chain Analysis
  • Figure 8: Global: H1N1 Vaccines Industry: Porter's Five Forces Analysis
  • Figure 9: Global: H1N1 Vaccines Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: H1N1 Vaccines (Intramuscular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: H1N1 Vaccines (Intramuscular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: H1N1 Vaccines (Intranasal) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: H1N1 Vaccines (Intranasal) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: H1N1 Vaccines (Intradermal) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: H1N1 Vaccines (Intradermal) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: H1N1 Vaccines (Public) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: H1N1 Vaccines (Public) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: H1N1 Vaccines (Private) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: H1N1 Vaccines (Private) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: North America: H1N1 Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: North America: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Europe: H1N1 Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Europe: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Asia Pacific: H1N1 Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Asia Pacific: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Middle East and Africa: H1N1 Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Middle East and Africa: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Latin America: H1N1 Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Latin America: H1N1 Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: H1N1 Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: H1N1 Vaccines Market Forecast: Breakup by Vaccines Type (in Million USD), 2026-2034
  • Table 3: Global: H1N1 Vaccines Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 4: Global: H1N1 Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: H1N1 Vaccines Market Structure
  • Table 6: Global: H1N1 Vaccines Market: Key Players